¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå, ¿¹Ãø(-2029³â)
Global Molecular Diagnostics Market, Forecast to 2029
»óǰÄÚµå : 1479979
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 62 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,767,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

ºÐÀÚÁø´ÜÀÌ ¼ºÀå ±âȸ¸¦ ºÒ·¯ÀÏÀ¸Å°°í, Çõ½ÅÀû ¸ÂÃãÇü ÀÇ·á·Î ³ª¾Æ°¥ ¼ö ÀÖ´Â ±æÀ» ¿­¾î

¼¼°è ºÐÀÚÁø´Ü ½ÃÀåÀº COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ ¼ö¿ä Áõ°¡, ¾Ï ȯÀÚ Áõ°¡, ºü¸¥ ±â¼ú ¹ßÀü µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Å« ÆøÀÇ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR), µðÁöÅÐ PCR, Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS) µî ±â¼úÀÇ ¹ßÀüÀ¸·Î ºÐÀÚ °Ë»çÀÇ Á¤È®¼º°ú »ý»ê¼ºÀÌ Çâ»óµÇ¾î °³Àκ° ¸ÂÃã Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù.

¿¹Ãø ºÐ¼®Àº Áö¿ª°ú ¿ëµµº°·Î ±¸ºÐµË´Ï´Ù. ÈÄÀÚ´Â °¨¿° °Ë»ç, Á¾¾ç °Ë»ç, À¯ÀüÀÚ °Ë»ç ¹× ±âŸ ºÐÀÚÁø´ÜÀ» Æ÷ÇÔÇϸç, Frost & SullivanÀÇ ÀÌ »ê¾÷ ¿¹ÃøÀº ¹æ¹ý·ÐÀû Á¦¾àÀ¸·Î ÀÎÇØ ¼ºÀå ±âȸ ºÐ¼®¿¡ ÁúÀû Á¢±Ù ¹æ½ÄÀ» »ç¿ëÇÕ´Ï´Ù.

¾Ï ¹ßº´·üÀÇ Áõ°¡·Î ÀÎÇØ ÷´Ü ºÐÀÚÁø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ °¡¼ÓÈ­µÇ°í, ¸¸¼º ÁúȯÀÇ Áõ°¡, Á¤ºÎÀÇ ÀÇ·á Çö´ëÈ­, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ºÐÀÚÁø´Ü »ê¾÷ÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á ±ÔÁ¦ÀÇ °­È­¿Í R&D ÅõÀÚ È®´ë´Â ÀÌ·¯ÇÑ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

¼ºÀå ȯ°æ

Àü·«Àû ¿øÄ¢

¼ºÀå ±âȸ ºÐ¼®

°³¿ä

¸ÅÃâ ¿¹Ãø

°æÀï »óȲ

ÀμöÇÕº´

ÁÖ¸ñ ±â¾÷

¼ºÀå ±âȸ À¯´Ï¹ö½º

´ÙÀ½ ½ºÅÜ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Molecular Diagnostics Unleash Growth Opportunities, Steering Innovation Personalized Medicine

The global molecular diagnostic market will experience significant growth due to a broad range of factors, such as increased demand from the COVID-19 pandemic, an increasing number of cancer cases, and the swift evolution of technological capabilities.

Technological advancements, such as polymerase chain reaction (PCR), digital PCR, and next-generation sequencing (NGS), have improved molecular testing accuracy and productivity, enabling personalized treatment.

The forecast analysis is segmented by region and by application. The latter includes infectious disease testing, oncology testing, genetic testing, and other molecular diagnostics. Frost & Sullivan's forecasts for this industry use a qualitative approach for the growth opportunity analyses due to methodological constraints.

The growing prevalence of cancer has accelerated the need for advanced molecular diagnostic tools, while the rise in chronic diseases, the modernization of government healthcare, and the growing demand for personalized medicine will contribute to the significant growth anticipated in the molecular diagnostics industry. Focused healthcare regulations and substantial R&D investments facilitate this expansion.

Table of Contents

Growth Environment

Strategic Imperatives

Growth Opportunity Analysis

Overview

Revenue Forecast

Competitive Landscape

Mergers and Acquisitions

Companies to Watch

Growth Opportunity Universe

Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â